Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Related Citations for PubMed (Select 16796777)

1.

Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma.

Barlogie B, Zangari M, Bolejack V, Hollmig K, Anaissie E, van Rhee F, Pineda-Roman M, Mohiuddin A, Crowley J, Tricot G.

Clin Lymphoma Myeloma. 2006 May;6(6):469-74.

PMID:
16796777
2.

Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma.

Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF, et al.

Blood. 1995 Jun 1;85(11):3077-85.

3.

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.

Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, Michallet M, Facon T, Garderet L, Marit G, Ketterer N, Lamy T, Voillat L, Guilhot F, Doyen C, Mathiot C, Moreau P.

J Clin Oncol. 2009 Dec 1;27(34):5720-6. doi: 10.1200/JCO.2008.21.1060. Epub 2009 Oct 13.

4.

Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients.

Scudla V, Bacovsky J, Indrak K, Kodouskova V, Vytrasova M, Faber E, Papajik T, Adam Z, Hajek R, Horak P, Martinek A; Czech Myeloma Group.

Hematol J. 2003;4(5):351-7.

PMID:
14502261
6.

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.

Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G.

Exp Hematol. 2003 Jan;31(1):73-80.

PMID:
12543109
7.

Hematopoietic stem cell transplants for multiple myeloma.

Tricot G, Jagannath S, Vesole DH, Bracy D, Desikan KR, Siegel D, Barlogie B.

Leuk Lymphoma. 1996 Jun;22(1-2):25-36. Review.

PMID:
8724525
8.

Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.

Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF, et al.

Stem Cells. 1995 Aug;13 Suppl 2:132-9.

PMID:
8520502
9.

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T.

Hematol J. 2002;3(4):185-92.

PMID:
12189564
10.

IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.

Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D.

Ann Hematol. 2005 Feb;84(2):115-7. Epub 2004 Oct 22.

PMID:
15503021
11.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J.

Blood. 1999 Jan 1;93(1):55-65.

12.

[Intensive treatment of multiple myeloma].

Harousseau JL.

Bull Acad Natl Med. 2003;187(2):405-13; discussion 413-5. Review. French.

PMID:
14556449
13.

Transplantation as salvage therapy for high-risk patients with myeloma in relapse.

Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G.

Bone Marrow Transplant. 2002 Dec;30(12):873-8.

14.

Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.

Harousseau JL, Attal M, Divine M, Milpied N, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, et al.

Bone Marrow Transplant. 1995 Jun;15(6):963-9. Review.

PMID:
7581098
15.

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.

Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J.

Blood. 2006 Apr 1;107(7):2633-8. Epub 2005 Dec 1.

17.

Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.

Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH; Korean Multiple Myeloma Working Party.

Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512.

PMID:
19285634
18.

Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.

Majolino I, Vignetti M, Meloni G, Vegna ML, Scimè R, Tringali S, Amaddii G, Coser P, Tribalto M, Raimondi R, Bergonzi C, Sajeva MR, Sica S, Ferrando F, Messina G, Mandelli F.

Haematologica. 1999 Sep;84(9):844-52.

19.

High-dose therapy followed by autologous haematopoietic stem cell transplantation in multiple myeloma.

Koh LP, Linn YC, Teoh G, Goh YT, Tan PH.

Ann Acad Med Singapore. 2002 Nov;31(6):731-7.

PMID:
12520826
20.

A systematic overview of chemotherapy effects in acute myeloid leukaemia.

Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):231-52. Review.

PMID:
11441935
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk